DEFA14A: NovaBay Pharmaceuticals Urges Stockholders to Approve Asset Sale and Dissolution at Reconvened Special Meeting

NovaBay Pharmaceuticals is urging stockholders to vote in favor of the proposed sale of its eyecare business and subsequent dissolution at a reconvened special meeting on December 18th.

Summary

• NovaBay Pharmaceuticals is seeking stockholder approval for the sale of its Avenova eyecare business to PRN Physician Recommended Nutriceuticals, LLC.
• The company is also proposing a complete liquidation and dissolution following the asset sale.
• A special meeting was initially held on November 22, 2024, but the required majority vote was not achieved, leading to a reconvened meeting on December 18, 2024.
• Stockholders who held shares as of October 15, 2024, are eligible to vote.
• The company's board of directors unanimously supports both proposals.
• The sale of the Avenova business is intended to monetize the value built over the past decade.
• PRN is expected to support the continued growth of the Avenova brand with its existing network of over 5,000 eyecare professionals.
• The company is urging stockholders to vote by December 17, 2024, at 11:59 p.m. Eastern time.

Sentiment

Score: 3

Explanation: The document indicates a significant negative event for the company, namely the sale of its primary asset and subsequent dissolution. While the sale is presented as a positive for the Avenova brand, the overall sentiment is negative for NovaBay as a going concern.

Positives

• The proposed sale of the Avenova business allows NovaBay to realize the value built in the brand over the past decade.
• PRN is a well-established eyecare company with the resources and leadership to support the continued growth of the Avenova brand.
• The transaction is supported by the board of directors and independent financial and legal advisors.
• PRN's existing network of over 5,000 eyecare professionals is expected to help expand the reach of Avenova products.

Negatives

• The company is proposing a complete liquidation and dissolution, which means the company will cease to exist after the sale.
• The initial special meeting on November 22, 2024, failed to achieve the required majority vote, indicating potential stockholder concerns or lack of engagement.
• The need to reconvene the special meeting suggests a lack of initial support for the proposals.

Risks

• The proposed asset sale and dissolution are subject to stockholder approval, and there is no guarantee that the required majority will be achieved.
• The company's future is dependent on the successful completion of the asset sale and subsequent liquidation.
• There are risks associated with the liquidation process, including the distribution of assets to stockholders.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially.

Future Outlook

The company's future is contingent on the successful completion of the proposed asset sale and subsequent liquidation and dissolution. The company expects the Avenova brand to continue to grow under PRN's ownership.

Management Comments

• CEO Justin Hall stated that the proposed transaction is fully supported by him and the Board of Directors.
• The Board of Directors believes the transaction is in the best interest of the stockholders.
• CEO Justin Hall urges stockholders to vote FOR Proposal One and Proposal Two.

Industry Context

The proposed sale of NovaBay's eyecare business to PRN reflects a trend of consolidation and strategic acquisitions within the eyecare industry. This move allows NovaBay to monetize its assets while placing the Avenova brand with a company that has the resources and network to support its growth.

Comparison to Industry Standards

• It is difficult to compare this specific transaction to industry standards as it involves the sale of a specific brand and the subsequent dissolution of the company.
• However, the sale of assets to a larger company with an established distribution network is a common strategy in the pharmaceutical and healthcare industries.
• The liquidation and dissolution of a company is not a standard practice, but it can occur when a company determines that it is the best way to maximize value for shareholders.

Stakeholder Impact

• Shareholders will receive proceeds from the liquidation, if approved, but will no longer have an investment in NovaBay.
• Employees may be impacted by the sale and dissolution, potentially leading to job losses.
• Customers of Avenova products will likely see a continuation of the brand under PRN's ownership.
• Suppliers and creditors will be impacted by the liquidation process.

Next Steps

• Stockholders are urged to vote on Proposal One and Proposal Two by December 17, 2024.
• The reconvened Special Meeting will be held on December 18, 2024, to finalize the vote.
• If approved, the company will proceed with the sale of the Avenova business and subsequent liquidation and dissolution.

Key Dates

Keywords

NovaBay Pharmaceuticals, Avenova, PRN Physician Recommended Nutriceuticals, Asset Sale, Liquidation, Dissolution, Special Meeting, Stockholders, Eyecare, Proxy Vote